All News

In recent years, the number of children diagnosed with additional autoimmune diseases accompanying type 1 diabetes (T1D) has increased, according to a study published in Frontiers in Endocrinology.

Among patients with advanced Parkinson disease and motor fluctuations, a combination of levodopa/carbidopa/entacapone was shown to improve motor and sleep symptoms.

Point-of-care diabetic retinopathy screening using autonomous artificial intelligence (AI) systems is effective and cost-saving for children with diabetes and their caregivers.

New data suggests a patient’s education level can be an important factor in the disease outcomes of patients with multiple myeloma.

Pralsetinib (Gavreto), developed by Blueprint Medicines, received accelerated approval. Thermo Fisher Scientific's Oncomine Dx Target Test received premarket approval as a companion diagnostic to identify patients who are candidates for the once-daily oral RET-targeted therapy.

AstraZeneca's phase 3 trial of a coronavirus disease 2019 (COVID-19) vaccine has been temporarily stopped; the Sturgis Motorcycle Rally may have led to over 250,000 COVID-19 cases; a potential treatment for breast cancer may not be effective.

Expanding traditional value frameworks to include inequality and factors that contribute to this is the first step to addressing disparities in health outcomes. Utilizing multi-criteria decision analysis and distributional cost effect analysis can assist in deriving data and subsequently acting on these issues.

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, discusses the potential of tiragolumab/atezolizumab for metastatic non–small cell lung cancer (NSCLC).

In findings from a novel global atlas study published today, 19 risk factors were identified to increase risk of developing type 2 diabetes, with insomnia identified as a risk factor for the first time.

Telehealth has been around for years in the United States, but it was not until the coronavirus disease 2019 (COVID-19) pandemic that it became so widely used.

Nine pharmaceutical companies issued a joint pledge that seeks to reassure the public about the safety, efficacy of their potential vaccines; fatigue, headache, and fever were indicated as the most common symptoms of COVID-19 in children; the link between vaping use and risk of COVID-19 infection and adverse outcomes becomes clear.

The top 3 issues relevant within cancer care delivery to be discussed at this year's virtual Patient-Centered Oncology Care Conference 2020 will include COVID-19, pharmacy benefit managers, and alternative payment models.

Each Patient-Centered Oncology Care meeting provides dynamic, provoking conversations on the current and future landscape of oncology. This year's PCOC 2020 will work to continue this trend.

While coronavirus disease 2019 (COVID-19) is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects and postinfection sequelae that aren’t yet fully known, said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.

Transitioning from population to precision health care, as well as eschewing old health care models of the past linked with misuse and excess cost, can assist in evolving the current US health care delivery system.

Children and adolescents initiating selective serotonin reuptake inhibitors (SSRIs) may be at a small increased risk of developing type 2 diabetes, according to a recent study published in JAMA Psychiatry.

A vaccine isn’t the panacea many assume it will be. Even when it becomes available, the virus won’t go away. Real world evidence will be needed to guide decision making.

With little research on the subject, the investigators sought out a connection between certain perinatal factors and risk of young-onset breast cancer in a sister-matched case-control study.

Providers need to focus on detecting and treating cardiovascular complications in at-risk patients, and not get lost in the fact they have COVID-19, said Manan Pareek, MD, PhD, FAHA, FESC, an internal medicine hospital resident at the Yale University School of Medicine.

A study using real-world data from an Italian region found two-thirds of patients with chronic migraine treated with erenumab transitioned to episodic migraine within 6 months.

The authors suggest that recognizing the possible link may help identify patients at greater risk, although they do caution that larger studies are needed.

For patients with systemic sclerosis, myopathy is a risk factor for worse outcomes and survival, according to a recent study.

There are now multiple therapeutic options available for spinal muscular atrophy (SMA), a disease once considered incurable; however, there remains a need for additional treatments and better ways to predict treatment response.

In the past 30 years, we've never seen a heart failure drug that has had such a beneficial effect on the kidneys, said Milton Packer, MD, a distinguished scholar in cardiovascular science at Baylor University Medical Center in Dallas, and chair of the department of clinical sciences at the University of Texas Southwestern Medical School.

New findings indicate that relying on circulating tumor DNA (ctDNA) and tissue DNA tests are complementary measures that can better match patients with biliary tract cancer with precise therapies.

A small study says that gloves with sensors could measure impairments in hand function and may have advantages over standard methods.

A healthy diet consisting of fruit, vegetables, and whole grains in middle age may be associated with fewer non-motor symptoms known to precede the diagnosis of Parkinson disease, according to study findings.

Remote patient monitoring of patients with COPD can offer clues about what happens before an exacerbation.

For patients with insomnia amid the COVID-19 pandemic, certain nightly habits can promote sleep hygiene; in addition, lemborexant has emerged as a novel indication if drug intervention is needed.

Findings from a new study in JAMA do not support the use of vitamin D3 supplementation to prevent severe asthma exacerbations in children with persistent asthma.